A phase I trial of extended release medtadoxine assessing adverse events

Trial Profile

A phase I trial of extended release medtadoxine assessing adverse events

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Metadoxine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Sponsors Alcobra
  • Most Recent Events

    • 13 Jan 2017 New trial record
    • 09 Jan 2017 According to an Alcobra media release, the US FDA has agreed to modify the Full Clinical Hold to a Partial Hold, pending review and approval of protocol for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top